Monday, October 20, 2014

UPDATING: CapitalHill Advisory Corrects Its Lobbying Disclosure Form: It Is "Our" Merck!

Well, the newly-amended form LD-2 removes all reference to the German company's address, and cleans up the typos in what the lobbying is about.

The same lobbying firm represents others, including Pfizer and Astra-Zeneca and Abbvie on these issues, so the less than $5,000 paid by Whitehouse Station is truly tiny. Here it is, as corrected:

. . . .Australian Government policy on intellectual property and its impact on the Australian healthcare system. . . Impact of Australian Government Policy on the company's local business environment. . . .

Now you know. Glad we were able to clear that up.

No comments: